Abstract
Since the different, so-called omics disciplines generate huge amount of data, the application of appropriate, sophisticated statistical methods for developing and validating predictive molecular signatures for drug development, for prevention, screening, diagnosis, monitoring of treatment or aftertreatment of diseases as well as for stratification of individuals is fundamental. The development and validation require several steps and it is quite a long journey from the detection of a molecular predictive signature to the routine use in clinical practice. In our review we focus on data obtained from cDNA expression microarrays. We describe the necessary development and validation steps including recent results of the second phase of the MAQC project (MAQC-II) and emphasise on potential pitfalls.
Keywords: Sample size planing, preprocessing, class prediction, internal validation, external validation
Current Molecular Medicine
Title: Development and Validation of Predictive Molecular Signatures
Volume: 10 Issue: 2
Author(s): M. Kohl
Affiliation:
Keywords: Sample size planing, preprocessing, class prediction, internal validation, external validation
Abstract: Since the different, so-called omics disciplines generate huge amount of data, the application of appropriate, sophisticated statistical methods for developing and validating predictive molecular signatures for drug development, for prevention, screening, diagnosis, monitoring of treatment or aftertreatment of diseases as well as for stratification of individuals is fundamental. The development and validation require several steps and it is quite a long journey from the detection of a molecular predictive signature to the routine use in clinical practice. In our review we focus on data obtained from cDNA expression microarrays. We describe the necessary development and validation steps including recent results of the second phase of the MAQC project (MAQC-II) and emphasise on potential pitfalls.
Export Options
About this article
Cite this article as:
Kohl M., Development and Validation of Predictive Molecular Signatures, Current Molecular Medicine 2010; 10 (2) . https://dx.doi.org/10.2174/156652410790963376
DOI https://dx.doi.org/10.2174/156652410790963376 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design A Facile Synthesis and Anticancer Activity Evaluation of Spiro Analogues of Benzothiazolylchromeno/pyrano Derivatives
Letters in Drug Design & Discovery Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets Gastrin-Releasing Peptide Receptors Regulate Proliferation of C6 Glioma Cells through a Phosphatidylinositol 3-Kinase-Dependent Mechanism
Current Neurovascular Research Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway
Current Cancer Therapy Reviews The Role of Foxp3 in Regulatory T Cell Differentiation and Function
Current Immunology Reviews (Discontinued) Screening of SLE-susceptible SNPs in One Chinese Family with Systemic Lupus Erythematosus
Current Bioinformatics Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Current Cancer Drug Targets Colorectal Cancer in Elderly Patients: From Best Supportive Care to Cure
Anti-Cancer Agents in Medicinal Chemistry Trifluoroibuprofen Inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in vivo Tumor Growth in Aggressive Prostate Cancer Models
Anti-Cancer Agents in Medicinal Chemistry Cryptotanshinone Induces Pro-death Autophagy through JNK Signaling Mediated by Reactive Oxygen Species Generation in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Building of Bio-complexes in Maxillofacial Tissue Engineering
Current Tissue Engineering (Discontinued) Patent Selections
Recent Patents on DNA & Gene Sequences Antitumor Effect of Cycle Inhibiting Factor Expression in Colon Cancer <i>via Salmonella</i> VNP20009
Anti-Cancer Agents in Medicinal Chemistry Medical Applications of Hyperthermia Based on Magnetic Nanoparticles
Recent Patents on Biomedical Engineering (Discontinued) Novel Carbamοyloxy Analogues of Tamoxifen: Synthesis, Molecular Docking and Bioactivity Evaluation
Letters in Drug Design & Discovery The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery GSTP1 Polymorphisms and their Association with Glutathione Transferase and Peroxidase Activities in Patients with Motor Neuron Disease
CNS & Neurological Disorders - Drug Targets Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy
Current Drug Targets